QQQ   314.01 (+0.69%)
QQQ   314.01 (+0.69%)
QQQ   314.01 (+0.69%)
QQQ   314.01 (+0.69%)
Log in
ASX:RHY

Rhythm Biosciences Limited (RHY.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Rhythm Biosciences Limited engages in developing and commercializing medical diagnostics technology in Australia and internationally. It is developing ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.

MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange ASX
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
Current SymbolASX:RHY
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.rhythmbio.com
PhoneN/A
EmployeesN/A

Debt

Debt-to-Equity Ratio2.30
Current Ratio2.52
Quick Ratio2.50

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$100,000.00
Price / Sales0.00
Cash FlowN/A
Price / Cash FlowN/A
Book ValueA$0.02 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive RHY News and Ratings via Email

Sign-up to receive the latest news and ratings for RHY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rhythm Biosciences Limited (RHY.AX) (ASX:RHY) Frequently Asked Questions

What stocks does MarketBeat like better than Rhythm Biosciences Limited (RHY.AX)?

Wall Street analysts have given Rhythm Biosciences Limited (RHY.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rhythm Biosciences Limited (RHY.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Rhythm Biosciences Limited (RHY.AX)'s key competitors?

Some companies that are related to Rhythm Biosciences Limited (RHY.AX) include (BUX) (BUX), 12144 (IME), BARD1 Life Sciences Limited (BD1.AX) (BD1), Charles River Laboratories International (CRL), Cryosite Limited (CTE.AX) (CTE), dorsaVi Ltd (DVL.AX) (DVL), Epigenomics (EPGNY), Eternity Healthcare (ETAH), Genetic Signatures Limited (GSS.AX) (GSS), Genetic Technologies Limited (GTG.AX) (GTG), Imagion Biosystems Limited (IBX.AX) (IBX), Integral Diagnostics Limited (IDX.AX) (IDX), Lifespot Health Ltd (LSH.AX) (LSH), Medical Imaging (MEDD) and OncoSil Medical Limited (OSL.AX) (OSL).
View all of RHY's competitors.

Who are Rhythm Biosciences Limited (RHY.AX)'s key executives?

Rhythm Biosciences Limited (RHY.AX)'s management team includes the following people:
  • Mr. Glenn Gilbert, CEO & COO
  • Dr. Trevor John Lockett Ph.D., Technical Director, Chair of the Clinical Advisory Board & Director
  • Mr. Adrien Michele Wing C.P.A., B.Bus, B.Acc, CPA, Company Sec. (Age 47, Pay $105.6k)
  • Ms. Pauline Moffatt, Joint Company Sec.

What is Rhythm Biosciences Limited (RHY.AX)'s stock symbol?

Rhythm Biosciences Limited (RHY.AX) trades on the ASX under the ticker symbol "RHY."

How big of a company is Rhythm Biosciences Limited (RHY.AX)?

Rhythm Biosciences Limited (RHY.AX) has a market capitalization of $0.00 and generates $100,000.00 in revenue each year.

What is Rhythm Biosciences Limited (RHY.AX)'s official website?

The official website for Rhythm Biosciences Limited (RHY.AX) is www.rhythmbio.com.

This page was last updated on 1/19/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.